INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-Emptive Therapy in AML): A Multi-Arm, Precision-Based, Recursive, Platform Trial

Measurable residual disease intervention in AML: a new therapeutic horizon

AH Wei, HJ Iland, CD DiNardo, J Reynolds

2026-01-01

Acute myeloid leukemia (AML) is a polyclonal malignancy marked by high relapse rates despite initial morphologic remission. Althou..

TP53 status and impact on AML prognosis within the ELN 2022 risk classification

S Fleming, XCH Tsai, R Morris, HA Hou, AH Wei

2023-12-07

This study reports the following: (1) frequency of TP53 comutation within each component of the European LeukemiaNet 2022 acute my..